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Editorial on the Research Topic
Nanosized Drug Delivery Systems: Colloids and Gels for Site Specific Targeting
Recent advances in nanomedicine and biomaterials have provided new promising tools for in vitro
models and targeted drug administration in vivo, aiming to increase efficacy while limiting side
effects. Nanosized drug delivery systems are designed to modify the biodistribution of therapeutic
agents, in order to enhance their accumulation in the pathological site. Bioactive molecules can be
either conjugated to or entrapped into colloidal nanocarriers. Biocompatible nanoparticles (NPs),
polymer nanotherapeutics, lipid-based nanomaterials may enhance the stability and the targeted
delivery of low molecular weight drugs, as well as nucleic acids and therapeutic proteins. Once
administered in vivo, these colloids will face sequential biological barriers, which represent a major
challenge for site specific drug delivery. A fine control of key physicochemical characteristics of
the nanocarriers, including size, drug loading, and functionality, may lead to a successful barrier
penetration and an effective release at the targeted site.
Thomas andWeber review current limitations of NP-based drug delivery by focusing on cancer
treatments. While enhanced permeability and retention (EPR) can result in drug accumulation in
malignant tissues, this effect is highly dependent on tumor type and location. In order to improve
drug delivery, drugs, and NPs with long half-lives are obtained by conjugation or coating with
hydrophilic polymers. Controlled activation approaches and active targeting to cancer cells or
specific cellular compartments are discussed in view of possible future developments.
Naturally derived polymers are increasingly used in therapeutics and diagnostics. Chitosan NPs
are known to be promising vehicles for drug, protein, and gene delivery. Their main drawback
resides in their low physical and chemical stability under biological conditions. In order to
overcome this limitation, Saeed et al. grafted chitosan to phthalic or phenylsuccinic acids and
then used polyphosphoric acid, hexametaphosphate, or tripolyphosphate to achieve ionotropic
complexation and covalent crosslinking by carbodiimide chemistry. The NPs showed high stability
and reproducibility, as well as cytotoxic activity once loaded with the chemotherapic doxorubicin.
Vashist et al. developed a smart strategy to prepare auto-fluorescent hydrogel NPs made
of hydroxyethyl cellulose and chitosan, using water-in-oil emulsion polymerization. These
nanoparticles guaranteed biocompatibility, stability, proper cellular uptake, and the ability to cross
a model of blood brain barrier. Moreover, their auto-fluorescence in a wide range of wavelengths
may be exploited in the field of theranostics to develop image-guided therapies for the central
nervous system.
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Recently, polymeric NPs have been tested as therapeutic
cancer vaccines, i.e., medical tools which are capable of
educating the immune system to fight tumors and prevent
cancer diseases. Briquez et al. discuss in their review the
principles and current strategies to engineer therapeutic cancer
vaccines, with a particular focus on the use of site-specific
targeting nanomaterials. They outline the type of immune
responses triggered by vaccination, with an overview of
the main components of cancer vaccines, describing how
nanomaterials can be engineered to improve pharmacokinetics
and pharmacodynamics of the vaccine.
Current barriers to clinical translation of NPs are mainly
related to the limited control over NP physicochemical properties
and robust scale-up of their production. Bovone et al. engineered
an automated coaxial jet mixer for the production of stable
and size-controlled polymeric NPs from chemically diverse
block copolymers. The jet mixer allowed a fine tuning of
the flow conditions and mixing of the copolymer-containing
organic phase and an aqueous stream, for the continuous
nanoprecipitation of polymeric NPs.
The advantage of protecting active compounds from the
environment during storage and transport, while achieving a safe
and controlled release, are also relevant for applications which are
far from healthcare. Vega-Vásquez et al. describe different types
of nanocarriers developed in the biomedical field which may
find applications in agriculture, specifically in the area of plant
breeding, growth promotion, disease control, and post-harvest
quality control, in order to improve plant and food production,
while reducing the impact on the environment.
Moncalvo et al. describe in their review the recent research
progress on nanosized delivery systems for therapeutic proteins,
highlighting future directions and challenges. Although the
impact of protein therapeutics in healthcare is steadily increasing,
their safety and efficacy are often limited by instability, short half-
life, and immunogenicity. Covalent attachment of biocompatible
polymers, as well as protein nanoencapsulation in colloidal
systems, are currently being investigated for overcoming these
limitations, with the potential to develop next-generation
protein therapeutics.
Smart hydrogels with highly ordered structures at the nano-
scale have been extensively investigated as advanced delivery
systems. These gels can act as efficient drug protectors,
especially for peptides and proteins with limited half-life, and
as targeted drug carriers for in situ controlled delivery. These
characteristics are particularly appealing in tissue engineering,
where extracellular matrix (ECM) mimetic biomaterials are
required for controlled release of soluble factors to stimulate
tissue regeneration.
Ren et al. review growth factor (GF) engineering strategies
for tissue regeneration. GF binding to provisional biomaterials
or even natural ECM serves as slow-delivery approach. The
stability of GFs may be enhanced by site specific PEGylation, by
the optimization of the primary structure or the modification
of proteolytic sites. GF signaling may also be improved by
modulating the receptor binding site, creating hybrid proteins
which engage alternative signaling pathways, or controlling the
GF availability to cell-surface receptors.
Hwang et al. review ECM-mimetic biomaterials for targeted
and sustained drug release. The broad repertoire of ECM
interactions with different cell-surface receptors can facilitate
cell-targeted delivery and improve the therapeutic efficiency of
drugs. In addition, the interaction between ECM components
and cellular receptors are exploited for intracellular delivery,
which may have a significant impact on disease treatment and
tissue regeneration.
Fattah and Ranga present the latest advances in engineering
organoids through a modular and orthogonal design of
biomimetic materials, and the use of NPs which are able
to modulate matrix and tissue mechanical stresses. Magnetic
NPs enable the localized mechanical manipulation of cells
and biomaterials during the establishment of organoids. Once
internalized by target cells, these NPs become tools for cell
stimulation and assembly of complex tissue structures.
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